Non-alcoholic fatty liver disease
Conditions
Interventions
Resistant starch group (RS):Resistant starch
Control starch group (CS):Control starch
Sponsors
Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Ethnic Chinese; 2. Liver steatosis diagnosed by ultrasonography; 3. Aged 18-70 years old; 4. Written informed consents must be obtained.
Exclusion criteria
Exclusion criteria: 1. Participants with diabetes mellitus 2. Participants with an alcohol consumption history of more than 20g per day for men and more than 10g per day for women 3. Participants with acute or chronic gastrointestinal diseases, malignant tumor or severe renal dysfunction 4. Pregnant, breastfeeding women or women planning to get pregnant 5. Participants using antibiotics within 3 weeks before or during the study 6. Participants with viral hepatitis, drug-induced liver disease, total parenteral nutrition, Wilson's disease, autoimmune liver disease and other specific diseases that can lead to fatty liver 7. Participants with routine use of prescription medicines or adjuvant Chinese and Western medicines (except regular contraceptives) 8. Participants expected to have poor compliance 9. Participants who have used weight loss medication or participated in weight-loss programs in the previous 3 months 10. Participants with mental disorders who cannot cooperate 11. Participants with pacemaker or metallic implants, claustrophobia or other conditions that would be unable to undergo magnetic resonance examinations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in intrahepatic triglyceride content (IHTC); | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in anthropometric indicators;Change in body composition;Change in subcutaneous fat area (SFA);Change in visceral fat area (VFA);Glycemic control;Change in insulin sensitivity;Change in liver and renal function;Change in lipid profiles;Change in cytokines;Change in multi-omics parameters;Single nucleotide polymorphism (SNP);The remission rate of NAFLD;Percent change in intrahepatic triglyceride content; | — |
Countries
China
Contacts
Public ContactWeiping Jia
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Outcome results
None listed